Oncology Trialists and Their Minions – ILCN.org (ILCN/WCLC)
Poet and ILCN Editor-in-Chief Corey Langer, MD, illustrates the build-up and anticipation surrounding the release of research data.
Related Articles
Enhancing cost-effectiveness considerations in the adoption of new drugs in Hong Kong | HKMJ
Hong Kong Med J 2025 Aug;31(4):312–5 | Epub 23 Jul 2025 https://doi.org/10.12809/hkmj2412259 © Hong Kong Academy of Medicine.
Finding the Right Match: Who Should Opt for Anti–CTLA-4 and Programmed Cell Death Protein-1 Combination Therapy?
The emergence of immune checkpoint inhibitors (ICIs) has profoundly changed the landscape of cancer treatment. These agents have revolutionized the way we approach various malignancies,…
Retrospective Data Highlight Improved Efficacy With Maintenance Therapy vs Treatment Breaks in mCRC: With Connie Lai, MD
Podcast 單集 · OncLive® On Air · 31/07/2025 · 5 分鐘
A Pragmatic Approach to Trial Design – ILCN.org (ILCN/WCLC)
Although the primary finding was not what investigators had hoped for, recent presentations by Drs. Karen Reckamp and Konstantin H. Dragnev highlighted Pragmatica-Lung’s success as…
IMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC – ILCN.org (ILCN/WCLC)
The updated data and a recently presented exploratory analysis show the benefits varied based on PD-L1 expression, which may be influenced by a variety of…
A Pragmatic Approach to Trial Design – ILCN.org (ILCN/WCLC)
Although the primary finding was not what investigators had hoped for, recent presentations by Drs. Karen Reckamp and Konstantin H. Dragnev highlighted Pragmatica-Lung’s success as…
IASLC Committee Spotlight: Multidisciplinary Clinical Science Committee – ILCN.org (ILCN/WCLC)
Dr. Tom Stinchcombe discusses how this new IASLC committee is aiming to define multidisciplinary care, improve global access, and support collaborative science.
精靈一點：軟組織肉瘤
#精靈一點 #軟組織肉瘤 #腫瘤1300-1400主題：軟組織肉瘤嘉賓：龍浩鋒醫生(香港中文大學醫學院腫瘤學系臨床副教授)1400-1500主題：三高自行停藥風險嘉賓：曾子欣醫生(心臟科專科醫生)
Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights
Sevabertinib shows promise as a targeted therapy for HER2-mutant non-small cell lung cancer, addressing significant treatment gaps in this area.
Rethinking Radiation: Adopting Hypofractionated Radiation Therapy – ILCN.org (ILCN/WCLC)
Drs. Puneeth Iyengar and Edward Christopher Dee discuss the potential clinical and environmental benefits of hypofractionated radiation therapy, along with the barriers to broader adoption.